Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$119.44

-4.56 (-3.68%)

11:37
03/25/19
03/25
11:37
03/25/19
11:37

Sarepta data does not change thesis on DMD program, says RBC Capital

RBC Capital analyst Brian Abrahams notes that Sarepta Theraputics this morning reported nine-month functional and creatine kinase data from baseline from the four patients in the Phase 1 open-label study of the company's micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy. Overall, Abrahams says the results show continued improvements in North Star Ambulatory Assessment functional scores vs. the baseline, and that while the update may not stop concerns, it does not change his overall thesis on the program, where he continues to believe the totality of expression, biomarker and functional data point to real benefits that should enable improvements supporting approval in ongoing/subsequent studies. Abrahams, who has an Outperform rating and $192 price target on Sarepta, says he would use weakness as a buying opportunity.

  • 25

    Mar

  • 19

    Aug

SRPT Sarepta
$119.44

-4.56 (-3.68%)

03/11/19
FBCO
03/11/19
NO CHANGE
Target $207
FBCO
Outperform
Sarepta price target raised to $207 from $189 at Credit Suisse
Credit Suisse analyst Martin Auster maintained an Outperform rating on Sarepta (SRPT) and raised his price target to $207 from $189. In a research note to investors, Auster says his bull thesis has strengthened further, and that he is growing increasingly comfortable that the company's Duchenne Muscular Dystrophy program may provide to be first-in-class as well as best-in-class. He sees the completion of Sarepta's manufacturing scale-up allowing for commencement of the confirmatory Phase 3 trial in late 2019 and initial Phase 1/2 data from Pfizer (PFE) in its DMD gene tx trial in Q3 as critical catalysts to drive share appreciation of the next nine months.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
03/25/19
HCWC
03/25/19
NO CHANGE
Target $267
HCWC
Buy
Sarepta data bode well for registration study, says H.C. Wainwright
The functional gains with Sarepta Therapeutics' SRP-9001 in this morning's data bode well for the registration study, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. Micro-dystrophin gene therapy appears to positively impact key functional endpoints with a 34% increase in NSAA scores, and a -20%, -29%, and -13% change in time to rise, four-minute stair climb, and time to 100 meters, respectively from baseline to day 270, says the analyst. While bears are likely to point to the large variability in CK, a 64% decline from baseline, while not quite the 90%-plus at an earlier time point, for a measurement that is uniquely susceptible to activity is more an attribute of increased functional capacity as opposed to waning of gene therapy's effectiveness hypothesis in the younger patients, contends Chattopadhyay. He has a Buy rating on Sarepta with a $267 price target.
03/25/19
JPMS
03/25/19
NO CHANGE
JPMS
Overweight
Data today reinforce Sarepta's 'pole position,' says JPMorgan
The updated data from the first four Duchenne muscular dystrophy patients of Sarepta Therapeutics' Phase 1/2 trial at nine months are "all directionally positive" on both biomarker and functional assessments, JPMorgan analyst Anupam Rama tells investors in a research note. The analyst is not surprised with the creatine kinase fluctuations as patients become more active and finds it important that all biomarker/functional endpoints were improved from baseline at nine months. While lingering questions about competition in the micro-dystrophin space remain, these data reinforce Sarepta's "pole position," Rama contends. He keeps an Overweight rating on the shares. The stock in morning trading is down 4%, or $4.53, to $117.73.

TODAY'S FREE FLY STORIES

UNVR

Univar

$23.15

0.22 (0.96%)

20:10
12/05/19
12/05
20:10
12/05/19
20:10
Hot Stocks
Univar to sell environmental sciences business to AEA Investors for $195M »

Univar announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$3.10

-0.195 (-5.93%)

20:04
12/05/19
12/05
20:04
12/05/19
20:04
Syndicate
Plug Power 40M share Secondary priced at $2.75 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RGLD

Royal Gold

$117.91

0.64 (0.55%)

, TECK

Teck Resources

$15.71

-0.11 (-0.70%)

20:03
12/05/19
12/05
20:03
12/05/19
20:03
Hot Stocks
Royal Gold updates on Andacollo Workers Union ratifying 36-month collective deal »

Royal Gold (RGLD)…

RGLD

Royal Gold

$117.91

0.64 (0.55%)

TECK

Teck Resources

$15.71

-0.11 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IR

Ingersoll-Rand

$128.95

1.405 (1.10%)

19:41
12/05/19
12/05
19:41
12/05/19
19:41
Upgrade
Ingersoll-Rand rating change  »

Ingersoll-Rand upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$119.86

2.42 (2.06%)

19:06
12/05/19
12/05
19:06
12/05/19
19:06
Hot Stocks
Intercept Phase 3 study for OCA in fibrosis patients published in The Lancet »

Intercept announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

HUN

Huntsman

$22.34

0.37 (1.68%)

18:52
12/05/19
12/05
18:52
12/05/19
18:52
Hot Stocks
Huntsman acquires Icynene-Lapolla for all-cash payment of $350M »

Huntsman announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

UBER

Uber

$28.65

-0.405 (-1.39%)

18:48
12/05/19
12/05
18:48
12/05/19
18:48
Hot Stocks
Uber: Non-consensual kissing of sexual body part reported in 1 in 3M U.S. trips »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.65

-0.405 (-1.39%)

18:45
12/05/19
12/05
18:45
12/05/19
18:45
Hot Stocks
Uber says fatal physical assault reported in 1 in every 122M U.S. trips »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOMO

Domo

$19.47

-0.19 (-0.97%)

, EZPW

Ezcorp

$5.21

-0.01 (-0.19%)

18:44
12/05/19
12/05
18:44
12/05/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Domo…

DOMO

Domo

$19.47

-0.19 (-0.97%)

EZPW

Ezcorp

$5.21

-0.01 (-0.19%)

DOCU

DocuSign

$69.51

-0.465 (-0.66%)

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

CLDR

Cloudera

$10.02

0.16 (1.62%)

MDLA

Medallia

$29.79

0.55 (1.88%)

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

AOBC

American Outdoor Brands

$9.42

0.38 (4.20%)

YEXT

Yext

$16.62

0.065 (0.39%)

PD

PagerDuty

$24.99

-0.66 (-2.57%)

SAIC

SAIC

$83.82

-0.57 (-0.68%)

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

KFY

Korn/Ferry

$40.26

0.39 (0.98%)

COO

Cooper Companies

$313.10

1 (0.32%)

GWRE

Guidewire

$119.32

0.68 (0.57%)

OKTA

Okta

$119.18

-2.64 (-2.17%)

UBER

Uber

$28.65

-0.405 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 16

    Dec

  • 17

    Dec

  • 17

    Dec

UBER

Uber

$28.65

-0.405 (-1.39%)

18:43
12/05/19
12/05
18:43
12/05/19
18:43
Hot Stocks
Uber says 107 total fatalities in 2017-2018 reported in relation to Uber app »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.65

-0.405 (-1.39%)

18:34
12/05/19
12/05
18:34
12/05/19
18:34
Periodicals
Breaking Periodicals news story on Uber »

Uber reports 3,000 sexual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$819.61

10.12 (1.25%)

18:33
12/05/19
12/05
18:33
12/05/19
18:33
Hot Stocks
Chipotle CEO: I took time to understand what makes us unique »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$26.02

0.36 (1.40%)

18:17
12/05/19
12/05
18:17
12/05/19
18:17
Hot Stocks
Rent-A-Center raises quarterly dividend to 29c from 25c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$76.66

0.01 (0.01%)

18:02
12/05/19
12/05
18:02
12/05/19
18:02
Hot Stocks
Black Hills utilities receive approval to upsize Renewable Ready program »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRIM

Primoris

$21.92

0.3 (1.39%)

18:02
12/05/19
12/05
18:02
12/05/19
18:02
Hot Stocks
Primoris awarded two pipeline contracts for over $45M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$35.94

-0.09 (-0.25%)

18:01
12/05/19
12/05
18:01
12/05/19
18:01
Hot Stocks
LeMaitre CFO sells 121K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLBK

Columbia Financial

$16.33

-0.24 (-1.45%)

18:01
12/05/19
12/05
18:01
12/05/19
18:01
Hot Stocks
Columbia Financial expands stock buyback to acquire additional 3M shares »

Columbia Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXS

Axis Capital

$58.42

0.31 (0.53%)

17:49
12/05/19
12/05
17:49
12/05/19
17:49
Hot Stocks
Axis Capital increases quarterly dividend 2.5% to 41c per share »

Axis Capital has declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PZZA

Papa John's

$59.67

-0.53 (-0.88%)

17:48
12/05/19
12/05
17:48
12/05/19
17:48
Periodicals
Former Papa John's CEO files suit against ad firm, Bloomberg says »

Papa John's founder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

THG

Hanover Insurance

$133.80

0.52 (0.39%)

17:47
12/05/19
12/05
17:47
12/05/19
17:47
Hot Stocks
Hanover Insurance raises dividend to 65c/shr, announces $2.50 special dividend »

The Hanover Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

17:46
12/05/19
12/05
17:46
12/05/19
17:46
Hot Stocks
Biohaven Pharmaceutical issued patent relating to troriluzole »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$15.32

-0.48 (-3.04%)

17:45
12/05/19
12/05
17:45
12/05/19
17:45
Upgrade
Morgan Stanley upgrades Epizyme to Overweight ahead of lymphoma data »

Morgan Stanley analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

THG

Hanover Insurance

$133.80

0.52 (0.39%)

17:44
12/05/19
12/05
17:44
12/05/19
17:44
Hot Stocks
Hanover Insurance announces $150M accelerated buyback »

The Hanover Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MAS

Masco

$46.01

0.445 (0.98%)

17:35
12/05/19
12/05
17:35
12/05/19
17:35
Hot Stocks
Masco CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$195.52

-1.13 (-0.57%)

17:31
12/05/19
12/05
17:31
12/05/19
17:31
Hot Stocks
Cigna's Foss acquires over 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.